Lipocine Inc. (LPCN)

Market Cap	17.39M
Revenue (ttm)	3.67M
Net Income (ttm)	-5.37M
Shares Out	5.35M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,791
Open	3.255
Previous Close	3.220
Day's Range	3.250 - 3.330
52-Week Range	2.684 - 8.708
Beta	1.33
Analysts	Strong Buy
Price Target	9.00 (+176.92%)
Earnings Date	Aug 7, 2025

About LPCN

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: LPCN
• Website: https://www.lipocine.com

Analyst Forecast

According to 2 analysts, the average rating for LPCN stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 176.92% from the latest price.

Price Target

$9.0

(176.92% upside)

Analyst Consensus: Strong Buy